MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

The Multidrug Resistance gene (MDR 1) is frequently expressed in acute myeloid leukaemia (AML). MDR 1 is associated with resistance to chemotherapy in vitro and with a poor response rate in AML. We have investigated the prognostic value of MDR 1 expression in relation to other patient characteristics with respect to response and survival.

[1]  Costan,et al.  Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.

[2]  P. Sonneveld,et al.  Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. , 1996, Blood.

[3]  O. Garson,et al.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.

[4]  M. Tribalto,et al.  Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. , 1996, Blood.

[5]  F. Appelbaum,et al.  Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. , 1995, Blood.

[6]  T. Hamblin.  Disappointments in treating acute leukemia in the elderly. , 1995, The New England journal of medicine.

[7]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[8]  P. Sonneveld,et al.  Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. , 1995, Leukemia.

[9]  J. Merlin,et al.  Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. , 1995, Blood.

[10]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[11]  P. Wood,et al.  P‐glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival , 1994, British journal of haematology.

[12]  R. West,et al.  The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. , 1994, British Journal of Cancer.

[13]  W. Dalton,et al.  Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Sonneveld,et al.  Modulation of multidrug-resistant multiple myeloma by cyclosporin , 1992, The Lancet.

[15]  M. Oken,et al.  Varying intensity of postremission therapy in acute myeloid leukemia. , 1992, Blood.

[16]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.

[17]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[18]  T. Grogan,et al.  Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. , 1991, Blood.

[19]  P. Sonneveld,et al.  Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Bloomfield,et al.  The clinical significance of karyotype in acute myelogenous leukemia. , 1989, Cancer genetics and cytogenetics.

[21]  D. Treille,et al.  Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy , 1989, British journal of haematology.

[22]  R. Gray,et al.  PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.

[23]  W. Hiddemann,et al.  Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[25]  D. S. Gordon,et al.  A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial. , 1984, Blood.

[26]  N. Nissen,et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.

[27]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  G. Mickisch.  Multidrug Resistance , 1996, Der Urologe A.

[30]  F. Baas,et al.  Mechanisms of multidrug-resistance , 1994 .

[31]  R. Arceci.  Clinical significance of P-glycoprotein in multidrug resistance malignancies. , 1993, Blood.

[32]  B. Sikic,et al.  Multidrug Resistance ( mdr l ) Gene Expression in Adult Acute Leukemias : Correlations With Treatment Outcome and In Vitro Drug Sensitivity , 2003 .

[33]  C. Bloomfield,et al.  Chromosomal abnormalities in myelodysplastic syndromes and acute myeloid leukemia. , 1990, Clinics in laboratory medicine.

[34]  J. Dongen,et al.  Immunological marker analysis of cells in the various hematopoietic differentiation stages and their malignant counterparts. , 1987 .

[35]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[36]  D.,et al.  Regression Models and Life-Tables , 2022 .